TL;DR
This meta-analysis of 26 randomized controlled trials (RCTs) involving 3098 patients suggests that combining Jianpi Bushen (JPBS), a traditional Chinese medicine, with standard chemotherapy significantly improves clinical outcomes, enhances immune function, and reduces adverse side effects in gastric cancer patients compared to chemotherapy alone. While promising, further high-quality, large-scale trials are needed to confirm these findings.
What Problem Does This Paper Address?
Gastric cancer remains a major global health challenge, with high incidence and mortality rates. While surgery and chemotherapy are primary treatments, chemotherapy often comes with severe adverse reactions and can lead to drug resistance, limiting its effectiveness. Patients undergoing treatment can also suffer from compromised immunity and other complications. Traditional Chinese Medicine (TCM) has a long history of use in managing complex diseases, and there's growing interest in its potential as an adjuvant therapy. This paper specifically investigates whether Jianpi Bushen (JPBS), a TCM formulation aimed at invigorating the spleen and tonifying the kidney, can enhance the efficacy and safety of chemotherapy for gastric cancer.
Methods
The researchers conducted a systematic meta-analysis of existing randomized controlled trials (RCTs). They performed a comprehensive literature search across multiple databases (PubMed, EMBASE, Cochrane Library, MEDLINE, CNKI, Wanfang Data, and VIP) up to October 2017. The inclusion criteria focused on RCTs evaluating JPBS combined with chemotherapy for gastric cancer. Key outcome measures included Karnofsky Performance Status (KPS), clinical curative efficiency, immune function markers (CD3+, CD4+, CD8+, etc.), blood system parameters (WBC, platelets, hemoglobin), and nonhematologic adverse reactions (gastrointestinal, neurotoxicity, hand-foot syndrome, myelosuppression). Data analysis was performed using Review Manager 5.3, employing fixed-effects or random-effects models based on heterogeneity. Study quality was assessed using the Cochrane Handbook for Systematic Reviews of Interventions.
Datasets
This paper is a meta-analysis, meaning it analyzes data from previously published studies. The "datasets" are the 26 individual randomized controlled trials (RCTs) that met the inclusion criteria. These studies were conducted in China and involved a total of 3098 participants (1726 in the experimental group and 1372 in the control group). No new datasets were created for this study.
Key Insights and Ideas
- Synergistic Efficacy: The most significant insight is that JPBS isn't just a passive add-on; it appears to work synergistically with chemotherapy to improve treatment outcomes beyond what chemotherapy alone can achieve.
- Immune System Boost: The findings strongly suggest that JPBS helps to bolster the patient's immune system, which is often compromised by cancer and chemotherapy. This is evidenced by increases in key immune cell markers like CD3+ and CD4+.
- Mitigating Chemotherapy's Toll: A crucial finding is JPBS's ability to significantly reduce the incidence and severity of common and debilitating chemotherapy side effects, such as blood toxicity (low WBC, platelets, hemoglobin), gastrointestinal issues, neurotoxicity, and hand-foot syndrome. This directly addresses a major challenge in cancer treatment.
- TCM's Role in Modern Oncology: This study contributes to the growing body of evidence supporting the integration of TCM into modern cancer care, moving beyond anecdotal evidence to quantitative analysis.
Key Results
The meta-analysis revealed several statistically significant improvements when JPBS was combined with chemotherapy:
- Clinical Curative Efficiency: An odds ratio (OR) of 1.44 (95% CI: 1.09, 1.90) indicated a statistically significant improvement in clinical curative efficiency.
- Karnofsky Performance Status (KPS): An OR of 2.86 (95% CI: 2.11, 3.86) showed a significant improvement in quality of life as measured by KPS.
- Immune Function:
- CD3+ expression: Mean difference (MD) of 8.13 (95% CI: 4.57 to 11.69)
- CD4+ expression: MD of 4.79 (95% CI: 2.83, 6.75)
- CD4+/CD8+ ratio: MD of 0.33 (95% CI: 0.23, 0.43)
- NK+ levels: MD of 2.41 (95% CI: 1.43, 3.39)
- Macrophage expression: MD of 2.53 (95% CI: -0.02, 5.08)
- Note: CD8+ expression showed no significant improvement (MD = -4.26, 95% CI: -7.03, -1.50), and E-rosette expression was not significantly affected.
- Blood System Safety:
- Reduced WBC decline: OR = 0.21 (95% CI: 0.16, 0.26)
- Reduced PLT decline: OR = 0.30 (95% CI: 0.19, 0.48)
- Reduced Hb decline: OR = 0.33 (95% CI: 0.19, 0.59)
- Nonhematologic Safety:
- Reduced gastrointestinal reactions: OR = 0.31 (95% CI: 0.24, 0.40)
- Reduced neurotoxicity: OR = 0.33 (95% CI: 0.20, 0.55)
- Reduced hand-foot syndrome: OR = 0.31 (95% CI: 0.21, 0.45)
- Reduced myelosuppression: OR = 0.31 (95% CI: 0.17, 0.56)
Limitations and Future Work
The authors acknowledge several limitations:
- Low Study Quality: Most included RCTs were of generally low methodological quality, with insufficient reporting on random sequence generation, allocation concealment, and blinding. This raises concerns about potential bias.
- Lack of Registration: None of the included studies were registered in a clinical trial registry, which is now a standard requirement.
- High Heterogeneity: Significant clinical heterogeneity was observed in some analyses, which can affect the reliability of the pooled results.
- Publication Bias: Funnel plots suggested potential publication bias, meaning studies with positive results might be more likely to be published.
- Language Barrier: Most studies were published in Chinese, potentially limiting the broader extrapolation of findings.
Future Work: The authors strongly recommend conducting more high-quality, large-sample, multicenter, prospective, randomized, and double-blind clinical trials to further validate the efficacy and safety of JPBS combined with chemotherapy for gastric cancer. Further research is also needed to elucidate the detailed mechanisms by which JPBS exerts its therapeutic effects.
Summary updated